查詢結果分析
相關文獻
- 新一代治療慢性B型肝炎藥物Telbivudine介紹
- 慢性B型肝炎治療的現況
- 慢性B型肝炎之治療
- 臺灣肝臟病系列(41):慢性B型肝炎HBsAg陰轉後的肝炎
- 慢性B型肝炎的藥物治療
- 慢性B型肝炎之自然病史
- 慢性B型肝炎之藥物治療
- Clinical Significance of Changes in Serum Hepatitis B Virus DNA Titer in Patients with Chronic Hepatitis B Treated with Interferon
- Acquired Immunodeficiency Syndrome and Cytomegalovirus Gastritis in a Patient with Decompensated Liver Cirrhosis and Hepatocellular Carcinoma: Report of a Case
- 慢性B型肝炎中西醫之治療
頁籤選單縮合
題名 | 新一代治療慢性B型肝炎藥物Telbivudine介紹=Telbivudine: A New Treatment for Chronic Hepatitis B |
---|---|
作者 | 劉素靜; 林梅芳; | 書刊名 | 藥學雜誌 |
卷期 | 26:1=102 2010.03[民99.03] |
頁次 | 頁20-25 |
分類號 | 418.285 |
關鍵詞 | 慢性B型肝炎; 喜必福; 病毒抑制; Chronic hepatitis B; Telbivudine; Viral suppression; |
語文 | 中文(Chinese) |
中文摘要 | B型肝炎治療的最終目標,為抑制病毒的複製,使得 B型肝炎的病毒量降至 PCR (Polymerase Chain Reaction)測不到的地步。實驗證實無論是亞洲人還是西方人在服藥4週後即有很好的病毒抑制效果。 Telbivudine(喜必福 )為新的抗病毒藥物, 2006年10月,經美國藥物食品管理局核准上市。 Telbivudine有很好的耐受性與其他的抗病毒要比較起來,並且沒有基因毒性,不會導致畸胎,所以懷孕分級為 B級,對於 B型肝炎感染又欲懷孕的婦女是一個很好的治療上的選擇。 |
英文摘要 | The ultimate goal of treatment is the suppression of HBV replication,and treatment to reduce serum HBV DNA to low or undetectable level. The experiment confirmed that regardless of being the Asian or the westerner takes medicine for 4 weeks later namely has the very good virus suppression. Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B. FDA was approved in late 2006. Telbivudine has been generally well tolerated, no dose-limiting toxicity has been observed. In contrast to other nucleoside analogues, Telbivudine has not been associated with inhibition of mammalian DNA polymerase with mitochondrial toxicity, The drug should be used during pregnancy that be best choice for chronic hepatitis B with pregnancy woman. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。